Colorectal Cancer Risk Perception on the Basis of Genetic Test Results in Individuals at Risk for Lynch Syndrome
Shilpa Grover(Brigham and Women's Hospital), Sapna Syngal(Dana-Farber Cancer Institute), Rowena Mercado(Dana-Farber Cancer Institute), Elena M. Stoffel(University of Michigan), Peggy Conrad(University of California, San Francisco), Stephen B. Gruber(University of Southern California), Daniel C. Chung(Icahn School of Medicine at Mount Sinai), Jonathan P. Terdiman(UCSF Helen Diller Family Comprehensive Cancer Center), Kristen Shannon(Massachusetts General Hospital), Amie Blanco(University of California, San Francisco), Beth Ford(Dana-Farber Cancer Institute), Wendy Kohlman(Brigham and Women's Hospital)
Cited by 25
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932